When was WaveBreak founded?

WaveBreak was founded in 2016 and raised its 1st funding round within a year of its incorporation.

Where is WaveBreak located?

WaveBreak is headquartered in Cambridge, United Kingdom.

Which legal entities is WaveBreak associated with?

WaveBreak is associated with WAVEBREAK THERAPEUTICS LIMITED and 1 other.

Is WaveBreak a funded company?

WaveBreak is a funded company, having raised a total of $64.3M across 6 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on May 06, 2016.

How much is WaveBreak worth?

The latest valuation of WaveBreak is £***** as of Apr 02, 2024.

When was the latest funding round of WaveBreak?

WaveBreak's latest funding was a $***** Series A round on Apr 02, 2024, with participation from 0 investor. Its primary sector is Neurology. Globally, the Neurology sector has seen $2.52B in funding in 2026 to date.

Where does WaveBreak rank among its competitors?

WaveBreak ranks 201st amongst 686 active competitors, of which 242 are funded. It stands 5th in terms of total funding among its competitors. The most recent competitor to raise funding was Lexicon Pharmaceuticals, which secured $55.7M in Feb, 2026.

Who are the top competitors of WaveBreak?

WaveBreak's top competitors include Sana Biotechnology, Alector and Adocia. Among them, Lexicon Pharmaceuticals secured the most recent funding round in February, 2026.

WaveBreak - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of small molecule therapeutics for neurological disorders. It offers drugs that targets the fleeting protein intermediates, the oligomers to treat Parkinson’s disease, Alzheimer’s disease, and ALS.

Website: wavebreaktx.com
Email ID: *****@wavebreaktx.com

Key Metrics

Founded Year

2016

Location

Cambridge, United Kingdom

Stage

Series A

Total Funding

$64.3M in 6 rounds

Latest Funding Round

Series A, Apr 02, 2024, $*****

Post Money Valuation

£***** as on Apr 02, 2024

Investors

The Baupost Group & 11 more

Ranked

201^st among 686 active competitors

Similar Companies

Sana Biotechnology & 856 more

View WaveBreak's full profile

WaveBreak is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Wren Therapeutics Limited CIN: 10054518 , United Kingdom, Active	Mar 09, 2016	-	39 (As on Dec 31, 2020)
WAVEBREAK THERAPEUTICS LIMITED CIN: 10054518 , United Kingdom, Active	Mar 09, 2016	-	-

WaveBreak has raised a total funding of $64.3M over 6 rounds. Its first funding round was on May 06, 2016. WaveBreak has 12 institutional investors.

Here is the list of recent funding rounds of WaveBreak:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 02, 2024	5913807	Series A	2434824	1580216	6706085	7256866
Feb 08, 2021	5104937	Series A	6334630	8263382	5589283	4072382
Dec 17, 2020	5694977	Series A	7351108	1811499	7904686	8469405

Access funding benchmarks and valuations. Sign up today!

View details of WaveBreak's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of WaveBreak include Sana Biotechnology, Alector and Adocia. Here is the list of Top 10 competitors of WaveBreak, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
2nd	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	73/100
3rd	Adocia 2005, Lyon (France), Public	Developer of therapeutics for the treatment of diabetes and obesity	$26M	Stifel, Smalt Capital & 6 others	69/100
4th	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
5th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Novartis Venture Fund & 16 others	67/100
6th	Lexicon Pharmaceuticals 1995, The Woodlands (United States), Public	Developer of small molecule drugs for diffrent health diseases	-	Bay City Capital, BCM Technologies & 3 others	67/100
7th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Sanofi, Orbimed & 5 others	67/100
8th	Rezolute 2012, Denver (United States), Public	Developing transformative therapies for rare diseases, focusing on hyperinsulinism (HI)	-	BVF Partners, Citadel & 8 others	67/100
9th	Zucara Therapeutics 2015, Vancouver (Canada), Series B	Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes	$50.8M	TIAP, Cdrd.ca & 14 others	66/100
10th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	SVB Securities, Collage Venture Partners	66/100
201st	WaveBreak 2016, Cambridge (United Kingdom), Series A	Developer of small molecule therapeutics for neurological disorders	$64.3M	The Baupost Group, University of Cambridge ... & 10 others	41/100